YbaƱez, Conchita N.
HRN: 22-17-30 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/06/2022
CO-AMOXICLAV 625MG (TAB)
11/06/2022
11/12/2022
PO
625 Mg
BiD
Wound Infection
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes